NCT01821716已完成2 期
Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract to Determine the Biological Activity in HEP Units.
Laboratorios Leti, S.L.4 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2013年3月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
- 试验地点
- 4
- 主要终点
- Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.
研究概览
简要总结
The objective of this study is to determine the biologic activity of a Dermatophagoides pteronyssinus allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
详细描述
This is an open, unblinded and non-randomized biological assay. The study design is a slight modification of the recommendations proposed by the Nordic Guidelines.
Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided written informed consent, appropriately signed and dated by the subject (or legal representative, if applicable).
- •Subject can be male or female of any race and ethnic group.
- •Age > and =18 years and < and =60 years at the study inclusion day.
- •Medical history of allergy with respiratory symptoms (rhinitis and /or rhinoconjunctivitis and/or asthma) to Dermatophagoides pteronyssinus.
- •Positive skin prick test with a standardized commercially available preparation of Dermatophagoides pteronyssinus allergen extract. The skin prick test will be considered positive if the test results in a wheal major diameter of at least 3 mm or an area at least 7 mm
- •Positive skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study
- •A positive test for specific IgE to Dermatophagoides pteronyssinus (CAP-RAST major or equal to 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
排除标准
- •Immunotherapy in the past 5 years with a Dermatophagoides pteronyssinus allergen extract or other mites allergen extracts known to interfere with the allergen to be tested, due to a high degree of cross-reactivity.
- •Use of drugs that may interfere with the skin reactions (e.g., antihistamines). See Appendix 1 of the protocol.
- •Treatment with any of the following medications: oral tricyclic or tetracyclic antidepressants or IMAOs, beta-blockers, chronic use of corticosteroids or use of oral or parenteral corticosteroids in repeated and intermittent patterns (10 mg/daily of prednisone or equivalent).
- •Women who are pregnant or period of breastfeeding and women with a pregnancy test positive during the visit 2, prior to the prick test.
- •Dermographism affecting the skin area at the test site at either study visit.
- •Atopic dermatitis affecting the skin area at the test site at either study visit.
- •Urticaria affecting the skin area at the test site at either study visit.
- •Diseases of the immune system relevant clinically, both autoimmune and immunodeficiencies.
- •Serious diseases not controlled that may increase the risk for the safety of the subjects involved in this study, including, but not limited to the following: heart failure, uncontrolled or severe respiratory diseases,endocrine diseases, clinically relevant kidney or liver diseases or hematological diseases.
- •Participation in any other clinical trial within 30 days (or 5 times the biological half-life of the research of the study product, whichever is longer) prior to the inclusion of the subject in this clinical trial.
- •Patients with diseases or conditions that limit the use of adrenaline (heart disease, severe hypertension...)
- •Severe psychiatric, psychological or neurological disorders
- •Abuse of alcohol, drugs or medicines in the previous year.
研究组 & 干预措施
1
Experimental
Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)
Positive control (10 mg/ml histamine dihydrochloride)
Negative control (glycerinated phenol saline solution)
干预措施: Prick test Dermatophagoides pteronyssinus allergen extract (Biological)
结局指标
主要结局
Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.
时间窗: Test sites should be inspected and recorded 15-20 min after application
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
To determine the minimum amount of Dermatophagoides pteronyssinus allergen extract producing a positive skin reaction.EUCTR2012-001939-31-ESABORATORIOS LETI S.L.
已完成
2 期
Efficacy of VALERGEN-DP sublingual vaccine in asthmatic adults.AsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessBronchial asthmaRPCEC00000034ational Biopreparations Center (BIOCEN)
已完成
2 期
Efficacy of VALERGEN-DP subcutaneous vaccine in asthmatic adultsBronchial asthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaRPCEC00000027ational Biopreparations Center (BIOCEN)
进行中（未招募）
不适用
Biological standardization of Dermatophagoides, Betulaceae and GraminaceaeEUCTR2012-001651-39-ITOFARMA
已完成
2 期
Evidence of the clinical efficacy of VALERGEN-DP vaccine in asthmaticsAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessBronchial asthmaRPCEC00000037ational Biopreparations Center (BIOCEN)